UK Markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
32.15-0.12 (-0.37%)
As of 2:30PM EDT. Market open.
People also watch
Full screen
Previous close32.27
Bid0.00 x
Ask0.00 x
Day's range32.03 - 32.24
52-week range25.25 - 36.82
Avg. volume1,523,050
Market cap210.72B
PE ratio (TTM)22.08
Earnings dateN/A
Dividend & yield1.03 (3.18%)
Ex-dividend date2017-03-15
1y target estN/A
Trade prices are not sourced from all markets
  • Reuters2 days ago

    Roche's Tecentriq receives positive opinion from EU medicines agency

    A European Medicines Agency (EMA) panel said on Friday it has recommended Roche's immunotherapy Tecentriq as a treatment for advanced bladder and lung cancer, setting the stage for European Commission approval this year. Roche received a positive opinion for the treatment from the EMA's Committee for Medicinal Products for Human Use (CHMP). Tecentriq, which Roche has designed to help the immune system find and kill tumours that otherwise may avoid detection, won approval in the United States this year as an initial treatment for bladder cancer.

  • TheStreet.com4 days ago

    5 New Breast Cancer Treatments That Are Helping to Save Lives

    In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.

  • Reuters - UK Focus5 days ago

    Poor test results for Roche cloud growth prospects

    A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. "Their impact in the second half might limit Roche's chances of upgrading 2017 guidance," he said.